PortfoliosLab logo
ACADIA Pharmaceuticals Inc. (ACAD)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US0042251084

CUSIP

004225108

IPO Date

May 27, 2004

Highlights

Market Cap

$2.53B

EPS (TTM)

$1.36

PE Ratio

11.13

PEG Ratio

-0.42

Total Revenue (TTM)

$751.97M

Gross Profit (TTM)

$693.08M

EBITDA (TTM)

$76.85M

Year Range

$13.40 - $20.68

Target Price

$24.47

Short %

12.39%

Short Ratio

8.62

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in ACADIA Pharmaceuticals Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


100.00%150.00%200.00%250.00%300.00%350.00%400.00%450.00%December2025FebruaryMarchAprilMay
121.04%
402.22%
ACAD (ACADIA Pharmaceuticals Inc.)
Benchmark (^GSPC)

Returns By Period

ACADIA Pharmaceuticals Inc. (ACAD) returned -19.29% year-to-date (YTD) and -14.14% over the past 12 months. Over the past 10 years, ACAD returned -9.00% annually, underperforming the S&P 500 benchmark at 10.31%.


ACAD

YTD

-19.29%

1M

1.37%

6M

-6.21%

1Y

-14.14%

5Y*

-21.90%

10Y*

-9.00%

^GSPC (Benchmark)

YTD

-4.26%

1M

11.24%

6M

-5.02%

1Y

8.55%

5Y*

14.02%

10Y*

10.31%

*Annualized

Monthly Returns

The table below presents the monthly returns of ACAD, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20251.69%5.04%-15.26%-12.10%1.44%-19.29%
2024-17.25%-10.30%-20.44%-9.63%-9.63%7.62%17.05%-12.83%-7.24%-5.14%11.86%12.44%-41.39%
202319.54%8.72%-9.04%13.34%10.17%1.91%22.09%-7.59%-22.87%8.30%-1.28%40.53%96.67%
2022-3.64%12.98%-4.68%-23.86%-12.42%-12.76%4.26%11.84%-0.43%-2.02%-2.81%2.18%-31.79%
2021-10.12%1.91%-47.31%-20.31%8.66%9.18%-11.32%-19.05%-5.14%8.07%6.96%21.56%-56.34%
2020-6.64%7.01%-1.15%14.34%2.84%-2.44%-14.24%-4.76%4.19%12.61%21.98%-5.65%24.96%
201940.88%16.33%1.32%-10.43%-0.25%11.42%-8.04%12.53%30.12%17.84%6.79%-5.54%164.56%
2018-0.66%-16.70%-9.81%-29.64%14.48%-15.64%-1.18%-5.77%45.99%-6.17%-2.16%-15.16%-46.30%
201719.94%10.18%-9.79%-0.15%-25.11%8.48%6.74%19.62%5.78%-7.54%-13.15%-0.46%4.40%
2016-41.96%-16.58%61.99%15.52%9.69%-8.38%14.11%-13.26%-1.00%-26.72%15.79%6.85%-19.10%
2015-4.16%24.78%-14.17%4.85%20.57%1.65%16.55%-24.95%-9.72%5.29%8.99%-6.06%12.28%
2014-6.76%21.46%-14.03%-17.26%2.58%9.39%-10.27%18.30%3.25%11.87%7.83%6.29%27.05%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ACAD is 35, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of ACAD is 3535
Overall Rank
The Sharpe Ratio Rank of ACAD is 3636
Sharpe Ratio Rank
The Sortino Ratio Rank of ACAD is 3434
Sortino Ratio Rank
The Omega Ratio Rank of ACAD is 3434
Omega Ratio Rank
The Calmar Ratio Rank of ACAD is 4141
Calmar Ratio Rank
The Martin Ratio Rank of ACAD is 3333
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for ACADIA Pharmaceuticals Inc. (ACAD) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The current ACADIA Pharmaceuticals Inc. Sharpe ratio is -0.29. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of ACADIA Pharmaceuticals Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00December2025FebruaryMarchAprilMay
-0.31
0.44
ACAD (ACADIA Pharmaceuticals Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


ACADIA Pharmaceuticals Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-80.00%-60.00%-40.00%-20.00%0.00%December2025FebruaryMarchAprilMay
-74.02%
-8.35%
ACAD (ACADIA Pharmaceuticals Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the ACADIA Pharmaceuticals Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the ACADIA Pharmaceuticals Inc. was 96.29%, occurring on Nov 12, 2010. Recovery took 645 trading sessions.

The current ACADIA Pharmaceuticals Inc. drawdown is 74.02%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-96.29%Mar 17, 20061175Nov 12, 2010645Jun 10, 20131820
-77.18%Jul 8, 2020493Jun 21, 2022
-73.99%Jul 20, 2015777Aug 17, 2018327Dec 5, 20191104
-40.8%Feb 28, 201432Apr 14, 2014161Dec 2, 2014193
-38.42%Dec 9, 201967Mar 16, 202029Apr 27, 202096

Volatility

Volatility Chart

The current ACADIA Pharmaceuticals Inc. volatility is 12.53%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%December2025FebruaryMarchAprilMay
12.53%
11.43%
ACAD (ACADIA Pharmaceuticals Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of ACADIA Pharmaceuticals Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of ACADIA Pharmaceuticals Inc., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 292.7% positive surprise.


-0.500.000.501.0020212022202320242025
0.86
0.05
Actual
Estimate

Valuation

The Valuation section provides an overview of how ACADIA Pharmaceuticals Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio

The chart displays the Price-to-Earnings (P/E) ratio for ACAD, comparing it with other companies in the Biotechnology industry. Currently, ACAD has a P/E ratio of 11.1. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.

PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for ACAD compared to other companies in the Biotechnology industry. ACAD currently has a PEG ratio of -0.4. This PEG ratio is negative, which typically signals that the company's earnings are expected to decline. A negative PEG is not considered meaningful for valuation purposes.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for ACAD relative to other companies in the Biotechnology industry. Currently, ACAD has a P/S ratio of 2.6. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for ACAD in comparison with other companies in the Biotechnology industry. Currently, ACAD has a P/B value of 3.4. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items